Affiliation: Stanford University
- Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of >or=500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946)S Kundu-Raychaudhuri
AIDS Clinical Trials Unit, Center for AIDS Research, Stanford University Medical Center, Stanford, California 94305 5107, USA
AIDS Res Hum Retroviruses 17:1371-8. 2001....
- A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patientsS K Kundu
Center for AIDS Research at Stanford, Stanford University Medical Center, California 94305 5107, USA
AIDS Res Hum Retroviruses 14:551-60. 1998..However, since no effect on viral load was observed there was no evidence that this approach provided clinical benefit...
- Role of preimmunization virus sequences in cellular immunity in HIV-infected patients during HIV type 1 MN recombinant gp160 immunizationS K Kundu
Center for AIDS Research at Stanford, Stanford University Medical Center, California 94305, USA
AIDS Res Hum Retroviruses 14:1669-78. 1998..This vaccine was also immunogenic as measured by gp160-specific lymphocyte-proliferative responses. However, increased immune responses did not impact the HIV load or CTL epitope sequences during therapy...